Methylprednisolone

What it is

Methylprednisolone is a synthetic glucocorticoid, a laboratory-made analogue of the steroid hormones produced by the adrenal cortex. It is supplied as tablets, as methylprednisolone sodium succinate for intravenous or intramuscular injection, and as methylprednisolone acetate as an injectable suspension for intramuscular, intra-articular or intralesional use. The label describes it as a glucocorticoid whose synthetic class is used primarily for potent anti-inflammatory effects in disorders of many organ systems. It is prescription-only in the United States.

What the research says

The evidence is strong that methylprednisolone suppresses inflammation and immune responses, and that this helps in some specific situations and harms in others. It reliably speeds recovery from a multiple sclerosis relapse in the first five weeks, but the label itself states it does not change the eventual outcome of the disease. In acute head injury a large randomised trial found it increased deaths. In cardiac surgery and in hospitalised COVID-19 patients, randomised trials found no benefit. Even short outpatient courses are followed by markedly higher rates of sepsis, blood clots and fractures, and adrenal suppression after stopping is common.

Evidence grade: Well established.

How it works

Drug class: Synthetic glucocorticoid (systemic corticosteroid)

Methylprednisolone acts like a stronger, longer-acting version of the body's own cortisol. It enters cells, binds the glucocorticoid receptor and changes which genes are switched on, which damps down the chemical signals that drive inflammation and blunts the immune response to a wide range of triggers. The same receptor action alters how the body handles sugar, protein, fat, salt and water, which is why its wanted and unwanted effects travel together. (Source 1)

What it is used for

• Placebo-controlled trials pooled in a Cochrane review show methylprednisolone makes a relapse less likely to worsen or stall over the first five weeks (odds ratio 0.37, 95% CI 0.24 to 0.57). A randomised trial showed oral dosing is not inferior to intravenous. Neither the trials nor the label support any effect on long-term disability. Evidence: established. (Source 2)
• The label approves methylprednisolone across a very long list of conditions, mostly as short-term adjunctive therapy to carry someone through a flare. For most individual entries on that list we found no modern outcome trial; the approval reflects decades-old practice rather than a trial for each condition. The label itself frames much of this use as short-term administration to tide the patient over an acute episode. Evidence: limited. (Source 3)
• The MRC CRASH trial randomised 10,008 adults with head injury and found a higher risk of death with a 48-hour methylprednisolone infusion than with placebo (25.7% vs 22.3%, relative risk 1.15). The trialists concluded corticosteroids should not be used routinely in head injury. Evidence: not-supported. (Source 4)
• A Cochrane review concluded that high-dose methylprednisolone within eight hours improves motor recovery. A later systematic review tied to a clinical practice guideline found no difference in motor scores at any time point overall, and only suggested the 24-hour infusion as an option within eight hours. The two readings of largely the same trials disagree. Evidence: disputed. (Source 5)
• The 7,507-patient SIRS trial found methylprednisolone did not reduce 30-day death (4% vs 5%, RR 0.87, 95% CI 0.70-1.07) or death plus major morbidity (24% vs 24%), and the authors said the trial does not support routine use. Evidence: not-supported. (Source 6)
• A 393-patient randomised placebo-controlled trial of intravenous methylprednisolone in hospitalised patients with COVID-19 found no reduction in 28-day mortality overall, and more need for insulin. Benefit in COVID-19 has been shown for dexamethasone, a different corticosteroid, not for methylprednisolone in this trial. Evidence: not-supported. (Source 7)
• Methylprednisolone acetate is commonly injected epidurally for spinal pain. The label states the safety and effectiveness of epidural administration of corticosteroids have not been established and that corticosteroids are not approved for this use, and it lists reported deaths, spinal cord infarction, paraplegia, quadriplegia, cortical blindness and stroke. Evidence: not-supported. (Source 8)
• The only adequately powered trial used prednisone rather than methylprednisolone. It found a modest improvement in function (Oswestry Disability Index 6.4 points at 3 weeks) but no improvement in leg pain, no difference in surgery rates, and adverse events in 49.2% versus 23.9% on placebo. Whether methylprednisolone dose packs behave the same way has not been tested in a trial of that size. Evidence: limited. (Source 9)

Interactions

• Grapefruit juice (pharmacokinetic study): Grapefruit juice blocks the gut and liver enzyme that breaks methylprednisolone down, so the same tablet gives a higher and longer-lasting blood level. In ten healthy people, double-strength grapefruit juice raised total exposure to a 16 mg dose by 75% and lengthened the half-life by 35%. The authors judged the clinical significance small but said high intakes might enhance the drug's effects in sensitive people. (Source 10)
• Liquorice (glycyrrhizin) (pharmacokinetic study): Glycyrrhizin, the active compound in liquorice root, slows the breakdown of corticosteroids. In six healthy men given intravenous prednisolone with and without oral glycyrrhizin, exposure rose, clearance fell and the steroid stayed in the body longer. The study used prednisolone, not methylprednisolone, so this is an extrapolation across closely related glucocorticoids rather than a direct methylprednisolone finding. (Source 11)
• Ketoconazole (and other strong enzyme inhibitors) (pharmacokinetic study): Ketoconazole markedly slows methylprednisolone clearance. In six healthy subjects given intravenous methylprednisolone, ketoconazole 200 mg/day for six days raised exposure by 135% and cut clearance by 60%, and deepened the suppression of the body's own cortisol. (Source 12)
• Phenobarbital, phenytoin, rifampin (label): These drugs speed up the liver enzymes that destroy methylprednisolone, so the usual dose can stop working. The label says a higher methylprednisolone dose may be needed to get the desired response while they are being taken. (Source 13)
• Ciclosporin (cyclosporin) (label): Each drug slows the other's breakdown, so side effects of either become more likely. The label notes convulsions have been reported when the two are used together. (Source 13)
• High-dose aspirin and salicylates (label): Methylprednisolone can increase the clearance of chronic high-dose aspirin, lowering salicylate levels; when the steroid is withdrawn, salicylate levels can rebound into the toxic range. The label also advises caution with aspirin in people with hypoprothrombinaemia. (Source 13)
• Warfarin and other oral anticoagulants (label): The direction of the interaction is not predictable. The label records reports of both enhanced and diminished anticoagulant effect, and says clotting tests should be monitored. (Source 13)
• Live and live-attenuated vaccines (label): Live vaccines are contraindicated at immunosuppressive doses of corticosteroids. Killed vaccines can be given but the immune response to them may be weaker. (Source 14)
• Dietary salt, potassium and calcium (label): Corticosteroids make the body hold on to salt and water and lose potassium, and they increase calcium loss in the urine. The label says salt restriction and potassium supplementation may be necessary, and that all corticosteroids increase calcium excretion. (Source 14)
• Alcohol (theoretical): We found no methylprednisolone-specific study of alcohol. The documented concern is indirect: the label tells prescribers to use steroids with caution where there is active or latent peptic ulcer, and steroid-related peptic ulcer with perforation and haemorrhage is listed among the drug's adverse reactions, so anything else that irritates the stomach lining shares that territory. Treat this as theory rather than measured interaction. (Source 15)

Stopping it

• The label says that after long-term therapy methylprednisolone should be withdrawn gradually rather than abruptly, and that the lowest effective dose should be used with gradual reduction where possible. (Source 16)
• Stopping can unmask drug-induced adrenal insufficiency. The label says this relative insufficiency may persist for months after therapy stops, so steroid should be restarted during any stressful illness in that window. (Source 17)
• A meta-analysis of 74 studies in 3,753 corticosteroid users concluded that adrenal insufficiency after stopping is frequent, that no route, dose or duration excludes it, and that clinicians should have a low threshold for testing people with vague symptoms after stopping. (Source 18)
• Alternate-day dosing is the label's named strategy for reducing withdrawal problems during long courses: giving twice the daily dose every other morning is described as limiting pituitary-adrenal suppression, Cushingoid change, corticoid withdrawal symptoms and growth suppression in children. (Source 16)

What goes wrong

In the largest trial ever done in head injury, a 48-hour methylprednisolone infusion increased the risk of death rather than reducing it. (Source 4)

• Randomized trial, High certainty.
• Size: 10,008 adults randomised; 6-month data for 9,673 (96.7%)
• Who: adults with head injury and a Glasgow Coma Scale score of 14 or less, randomised within 8 hours of injury.
• How long: 48-hour infusion, outcomes to 6 months.
• Result: death 1248/4854 (25.7%) with corticosteroid vs 1075/4820 (22.3%) with placebo, relative risk 1.15, 95% CI 1.07-1.24, p=0.0001 (an absolute increase of about 3.4 percentage points, arithmetic from the two reported percentages); death or severe disability 38.1% vs 36.3%, RR 1.05, 0.99-1.10, p=0.079.
• Funding: not stated in the abstract (MRC-coordinated academic trial, ISRCTN74459797)

The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, 95% CI 1.07-1.24; p=0.0001)

Methylprednisolone acetate is widely injected into the epidural space for back and leg pain, but the label states this use is neither approved nor shown to be safe and effective, and serious neurological events including deaths have been reported. (Source 8)

• Official position, Certainty not rated.
• Size: not applicable (postmarketing reports summarised in the label)
• Who: people receiving epidural corticosteroid injections.
• How long: not applicable.
• Result: reported events include spinal cord infarction, paraplegia, quadriplegia, cortical blindness and stroke, with and without fluoroscopy; no rate is given.
• Funding: not applicable (FDA-approved labelling)

Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.

A large claims-based cohort and self-controlled case series found that short courses of oral corticosteroids were followed by sharply higher rates of sepsis, venous blood clots and fractures in the next 30 days. (Source 19)

• Cohort study, Certainty not rated.
• Size: 1,548,945 adults, of whom 327,452 (21.1%) received a short course.
• Who: US adults aged 18 to 64 continuously enrolled in private insurance from 2012 to 2014.
• How long: courses of less than 30 days; risk windows of 30 days and 31-90 days.
• Result: within 30 days: sepsis incidence rate ratio 5.30 (95% CI 3.80 to 7.41), venous thromboembolism 3.33 (2.78 to 3.99), fracture 1.87 (1.69 to 2.07); risk persisted below 20 mg/day prednisone equivalent (4.02, 3.61 and 1.83)
• Funding: not stated in the abstract (US academic analysis of a private insurance claims dataset)

Within 30 days of drug initiation, there was an increase in rates of sepsis (incidence rate ratio 5.30, 95% confidence interval 3.80 to 7.41), venous thromboembolism (3.33, 2.78 to 3.99), and fracture (1.87, 1.69 to 2.07)

A meta-analysis of 74 studies found that adrenal insufficiency after corticosteroid treatment is common, and that no route, dose or duration rules it out. (Source 20)

• Meta-analysis, Certainty not rated.
• Size: 74 articles with 3,753 participants.
• Who: adult corticosteroid users tested for adrenal insufficiency, across many underlying conditions and routes of administration.
• How long: varied; stratified by treatment duration from under 28 days to over one year.
• Result: adrenal insufficiency in 4.2% with nasal administration (95% CI 0.5-28.9) up to 52.2% with intra-articular administration (40.5-63.6); by dose 2.4% (0.6-9.3) low to 21.5% (12.0-35.5) high; by duration in asthma 1.4% (0.3-7.4) under 28 days to 27.4% (17.7-39.8) over one year.
• Funding: not stated in the abstract.

Stratified by administration form, percentages of patients with adrenal insufficiency ranged from 4.2% for nasal administration (95% confidence interval [CI], 0.5-28.9) to 52.2% for intra-articular administration (95% CI, 40.5-63.6).

The label lists a long range of harms from systemic methylprednisolone, from fluid retention and muscle wasting to peptic ulcer, osteoporosis, tendon rupture and Cushingoid changes, without giving rates. (Source 21)

• Official position, Certainty not rated.
• Size: not applicable (regulatory label listing, label version published 2026)
• Who: people taking methylprednisolone tablets.
• How long: not specified; many of the listed harms are described elsewhere in the label as depending on dose and duration.
• Result: no frequencies are given for any listed reaction.
• Funding: not applicable (FDA-approved labelling)

Muscle weakness Loss of muscle mass Steroid myopathy Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Dermatologic Impaired wound healing Petechiae and ecchymoses May suppress reactions to skin tests Thin fragile skin Facial erythema Increased sweating Neurological Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Development of Cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Menstrual irregularities Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus

The label warns that methylprednisolone suppresses the immune system and that the rate of infectious complications rises as the dose rises. (Source 22)

• Official position, Certainty not rated.
• Size: not applicable (regulatory label position, label version published 2026)
• Who: people taking methylprednisolone.
• How long: not specified.
• Result: no rates given; the label states the rate increases with increasing dosage.
• Funding: not applicable (FDA-approved labelling)

Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

The label warns that psychiatric reactions, from euphoria and insomnia to severe depression and frank psychosis, can appear on corticosteroids. (Source 17)

• Official position, Certainty not rated.
• Size: not applicable (regulatory label position, label version published 2026)
• Who: people taking corticosteroids.
• How long: not specified.
• Result: no rates given.
• Funding: not applicable (FDA-approved labelling)

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations.

What the evidence supports

A Cochrane review of placebo-controlled trials found that methylprednisolone or ACTH made an acute multiple sclerosis relapse less likely to worsen or stay unchanged in the first five weeks, but the trials were small and gave no information beyond one year. (Source 2)

• Systematic review, Certainty not rated.
• Size: 377 participants randomised across 6 trials (199 treatment, 178 placebo); methylprednisolone was studied in 4 of them, in 140 patients.
• Who: people with multiple sclerosis treated for an acute exacerbation, no age or severity restriction.
• How long: short-term (within the first five weeks); only one study of 51 patients reported one-year follow-up.
• Result: odds ratio 0.37, 95% CI 0.24 to 0.57 for the disease getting worse or staying stable within the first five weeks.
• Funding: not stated in the abstract (Cochrane review; the authors contacted trialists and pharmaceutical companies)

Limit of this finding: The review's own sentence is garbled and is quoted as printed: 'a protective effect against the disease getting worse or stable' reads as though staying stable were a bad thing. 'Worse or stable' is how the review defined the outcome it counted - relapses that got worse or failed to improve - so the odds ratio of 0.37 means fewer people were left worse or unimproved at five weeks on treatment than on placebo. Do not read the sentence as saying the drug stops the disease being stable. The review is also from 2000 and rests on six small trials totalling 377 people.

Overall, MP or ACTH showed a protective effect against the disease getting worse or stable within the first five weeks of treatment (odds ratio[OR]=0.37, 95% confidence interval [CI] 0.24-0.57) with some but non significant greater effect for MP and intravenous administration.

A randomised non-inferiority trial found that three days of oral high-dose methylprednisolone was not inferior to the same dose given intravenously for recovery from a multiple sclerosis relapse. (Source 23)

• Randomized trial, Certainty not rated.
• Size: 199 patients randomised (100 oral, 99 intravenous); per-protocol population 82 oral and 90 intravenous.
• Who: adults aged 18-55 with relapsing-remitting multiple sclerosis who had a relapse within the previous 15 days, at 13 French MS centres.
• How long: 3 days of treatment, primary endpoint at day 28.
• Result: 66 (81%) of 82 in the oral group and 72 (80%) of 90 in the intravenous group reached the primary endpoint; absolute treatment difference 0.5%, 90% CI -9.5 to 10.4; insomnia 77% oral vs 64% intravenous.
• Funding: French Health Ministry, Ligue Francaise contre la SEP, and Teva (a pharmaceutical company) per the funding statement.

In the per-protocol population, 66 (81%) of 82 patients in the oral group and 72 (80%) of 90 patients in the intravenous group achieved the primary endpoint (absolute treatment difference 0·5%, 90% CI -9·5 to 10·4).

A Cochrane review concluded that high-dose methylprednisolone given within eight hours improves motor recovery after acute spinal cord injury; this conclusion is contested (see disagreements). (Source 5)

• Systematic review, Very low certainty.
• Size: 8 trials included, 7 using methylprednisolone (participant total not given in the abstract)
• Who: people with acute spinal cord injury.
• How long: treatment within 8 hours of injury, 23- or 48-hour infusions, outcomes up to one year.
• Result: the review reports significant recovery of motor function when treatment began within eight hours, and no evidence of significantly increased complications or mortality from 23- or 48-hour therapy.
• Funding: not stated in the abstract.

Limit of this finding: The quotation is accurate but the conclusion is dated. This is the 2012 version of the Cochrane review; since then major spinal injury guidelines have moved away from routinely giving high-dose methylprednisolone after acute spinal cord injury, and the later systematic review recorded beside this one found no difference in motor score change at any time point. The review's text also contains its own typographical errors ('methyprednisolne', 'Data was obtained'), which are kept as printed because the passage is quoted verbatim.

Methylprednisolone sodium succinate has been shown to improve neurologic outcome up to one year post-injury if administered within eight hours of injury and in a dose regimen of: bolus 30mg/kg over 15 minutes, with maintenance infusion of 5.4 mg/kg per hour infused for 23 hours.

What the evidence does not support

In the same Cochrane review, the single trial with a year of follow-up found no difference between oral methylprednisolone and placebo in preventing new relapses or improving long-term disability. (Source 2)

• Systematic review, Certainty not rated.
• Size: one study with 51 patients within the review.
• Who: people with multiple sclerosis treated for an acute exacerbation.
• How long: one year; no data beyond one year.
• Result: no difference reported between oral methylprednisolone and placebo for new exacerbations or long-term disability; no data available beyond one year.
• Funding: not stated in the abstract.

Only one study (with 51 patients) reported data after one year of follow-up: no difference between oral MP and placebo in the prevention of new exacerbations or improvement in long term disability was detected. No data are available beyond one year of follow-up to indicate whether steroids or ACTH have any effect on long-term progression.

The methylprednisolone tablet label itself states that corticosteroids speed recovery from a multiple sclerosis relapse but do not change the eventual outcome or the natural history of the disease. (Source 24)

• Official position, Certainty not rated.
• Size: not applicable (regulatory label position, label version published 2026)
• Who: people with multiple sclerosis.
• How long: not stated.
• Result: no effect on the ultimate outcome or natural history of the disease; relatively high doses are needed for any significant effect.
• Funding: not applicable (FDA-approved labelling)

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease.

In a 7,507-patient randomised trial, methylprednisolone did not reduce death or major complications after cardiac surgery with cardiopulmonary bypass. (Source 6)

• Randomized trial, High certainty.
• Size: 7,507 patients randomised (3,755 methylprednisolone, 3,752 placebo), complete 30-day data for all.
• Who: adults aged 18 or older at high risk of morbidity and mortality (EuroSCORE at least 6) having cardiac surgery with cardiopulmonary bypass, at 80 centres in 18 countries.
• How long: two 250 mg doses on the day of surgery; outcomes at 30 days.
• Result: death 154 (4%) vs 177 (5%), RR 0.87, 95% CI 0.70-1.07, p=0.19; death or major morbidity 909 (24%) vs 885 (24%), RR 1.03, 95% CI 0.95-1.11, p=0.52; infection 465 (12%) vs 493 (13%); delirium 295 (8%) vs 289 (8%)
• Funding: Canadian Institutes of Health Research (public funder) per the funding statement.

Methylprednisolone, compared with placebo, did not reduce the risk of death at 30 days (154 [4%] vs 177 [5%] patients; relative risk [RR] 0·87, 95% CI 0·70-1·07, p=0·19) or the risk of death or major morbidity (909 [24%] vs 885 [24%]; RR 1·03, 95% CI 0·95-1·11, p=0·52).

A placebo-controlled randomised trial of intravenous methylprednisolone in hospitalised patients with COVID-19 found no reduction in 28-day death rates overall. (Source 7)

• Randomized trial, Certainty not rated.
• Size: 416 randomised, 393 analysed (194 methylprednisolone, 199 placebo)
• Who: hospitalised patients aged 18 or older with suspected COVID-19 at a tertiary centre in Manaus, Brazil; infection confirmed by PCR in 81.3%.
• How long: 0.5 mg/kg intravenously twice daily for 5 days; outcome at 28 days.
• Result: 28-day mortality not different between groups; patients over 60 in the methylprednisolone group had a lower 28-day mortality in a subgroup analysis; more insulin therapy needed in the methylprednisolone arm.
• Funding: not stated in the abstract (investigator-led Phase IIb trial, NCT04343729)

The mortality rates at Day 28 were not different between groups. A subgroup analysis showed that patients over 60 years old in the MP group had a lower mortality rate at Day 28. Patients in the MP arm tended to need more insulin therapy, and no difference was seen in virus clearance in respiratory secretion until Day 7.

A later guideline-linked systematic review found no difference in motor score change at any time point between people with spinal cord injury given methylprednisolone and those not given steroids. (Source 25)

• Systematic review, Low certainty.
• Size: not stated in the abstract (systematic review underpinning an AOSpine/Global Spine Journal guideline)
• Who: adults with acute spinal cord injury.
• How long: 6 and 12 months.
• Result: no differences in motor score change at any time point overall; modest improvements in mean motor scores at 6 and 12 months when methylprednisolone was given within 8 hours; no statistical difference in complication risk.
• Funding: not stated in the abstract (guideline development group)

there were no differences in motor score change at any time point in patients treated with MPSS compared to those not receiving steroids;

Where the evidence is mixed

In a randomised trial of a short tapering course of oral prednisone (a closely related glucocorticoid, not methylprednisolone) for sciatica from a herniated disc, function improved modestly but pain did not, and adverse events were twice as common. (Source 9)

• Randomized trial, Certainty not rated.
• Size: 269 adults randomised 2:1 (181 prednisone, 88 placebo)
• Who: adults with radicular pain for 3 months or less, Oswestry Disability Index 30 or higher, and an MRI-confirmed herniated disc in a Northern California health system.
• How long: 15-day tapering course (600 mg prednisone in total); outcomes at 3 weeks and 52 weeks.
• Result: Oswestry Disability Index 6.4 points better at 3 weeks (95% CI 1.9-10.9, p=.006) and 7.4 points at 52 weeks (2.2-12.5, p=.005); leg pain difference 0.3 points at 3 weeks (-0.4 to 1.0, p=.34); one or more adverse events 49.2% vs 23.9%, p<.001.
• Funding: not stated in the abstract (NCT00668434, conducted in an integrated health care delivery system)

Having 1 or more adverse events at 3-week follow-up was more common in the prednisone group than in the placebo group (49.2% vs 23.9%; P < .001).

Where the research disagrees

Whether high-dose methylprednisolone within eight hours helps after an acute spinal cord injury

• Cochrane review of steroids for acute spinal cord injury (2012), systematic review of 8 randomised trials, 7 using methylprednisolone: "Methylprednisolone sodium succinate has been shown to improve neurologic outcome up to one year post-injury if administered within eight hours of injury" (Source 5)
• Systematic review underpinning the AOSpine clinical practice guideline (2017), systematic review with GRADE-based guideline recommendations: "there were no differences in motor score change at any time point in patients treated with MPSS compared to those not receiving steroids", and the guideline only suggests a 24-hour infusion within 8 hours "as a treatment option" (Source 25)

Whether short courses of oral corticosteroids are low-risk

• US population-based cohort and self-controlled case series (2017), retrospective cohort plus self-controlled case series in 1,548,945 adults: "Within 30 days of drug initiation, there was an increase in rates of sepsis (incidence rate ratio 5.30, 95% confidence interval 3.80 to 7.41), venous thromboembolism (3.33, 2.78 to 3.99), and fracture (1.87, 1.69 to 2.07)" (Source 19)
• FDA-approved methylprednisolone tablet label, regulatory position, not an outcome study: The label gives no frequency for any adverse reaction and frames risk as a case-by-case judgement: "Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case" (Source 24)

How much

• Reference intake: There is no reference intake for a prescription corticosteroid; the dose is set by the prescriber. As a position, the FDA label (methylprednisolone tablets, label version published 2026) states an initial range of 4 mg to 48 mg per day depending on the condition, and insists requirements be individualised. (Source 26)
• Upper limit: No upper limit in the nutritional sense exists. As a position, the label's stated initial range tops out at 48 mg per day for tablets, while noting that selected patients may require higher initial doses; parenteral and pulse regimens used in trials run far higher. (Source 26)
• Studied: MRC CRASH gave a 48-hour intravenous corticosteroid (methylprednisolone) infusion within 8 hours of head injury to 10,008 adults. (Source 4)
• Studied: COPOUSEP gave methylprednisolone 1000 mg once a day for 3 days, orally or intravenously, for a multiple sclerosis relapse. (Source 23)
• Studied: SIRS gave methylprednisolone 250 mg at anaesthetic induction and 250 mg at the start of cardiopulmonary bypass. (Source 6)
• Studied: Metcovid gave intravenous methylprednisolone 0.5 mg/kg twice daily for 5 days in hospitalised COVID-19 patients. (Source 7)
• Studied: The label's multiple sclerosis regimen is quoted as 200 mg of prednisolone daily for a week then 80 mg every other day for a month, with 4 mg of methylprednisolone stated as equivalent to 5 mg of prednisolone. (Source 16)
• Studied: The grapefruit juice interaction study gave a single 16 mg oral dose of methylprednisolone to ten healthy volunteers. (Source 27)

A common belief, and what the research shows

The belief: A short steroid burst is a harmless way to settle inflammation.

What the research shows: Short courses are common and often useful, but they are not consequence-free. A cohort of 1,548,945 US adults in which "Of 1 548 945 adults, 327 452 (21.1%) received at least one outpatient prescription for short term use of oral corticosteroids over the three year period" found that "The increased risk persisted at prednisone equivalent doses of less than 20 mg/day". And a meta-analysis concluded "Adrenal insufficiency after discontinuation of glucocorticoid occurs frequently".

Questions and answers

What is it?

Methylprednisolone is a man-made glucocorticoid: a synthetic version of the steroid hormones the adrenal glands make. It is taken as tablets, injected into muscle or vein, or injected into a joint or soft tissue, and it is sold under names including Medrol, Solu-Medrol and Depo-Medrol. It is a prescription-only medicine. Unlike the natural hormones hydrocortisone and cortisone, it is used mainly for its anti-inflammatory strength rather than as hormone replacement. (Source 1)

What does it do in the body?

It damps down inflammation and suppresses the immune system across many organ systems, and it also changes how the body handles sugar, salt, fat and protein. The label describes glucocorticoids as causing profound and varied metabolic effects as well as modifying immune responses. That breadth is why it works in so many conditions and also why it causes so many side effects. (Source 1)

Is it good or bad for you?

Both, and the balance depends entirely on the setting. It reliably speeds recovery from a multiple sclerosis relapse, and short courses relieve many inflammatory flares. But in head injury a 48-hour infusion increased deaths (25.7% vs 22.3%), and even brief outpatient courses were followed by far higher rates of sepsis, blood clots and fractures. It is a drug whose benefit has to be specific to the condition being treated. (Source 4)

How do you get more of it?

It is not something to obtain more of. It is a prescription medicine and the label states that dose requirements vary and must be individualised to the disease and the patient's response, with an initial range of 4 mg to 48 mg a day for tablets. There is no food or supplement source. Only a prescriber sets or changes the dose. (Source 26)

If it is harmful, what reduces it?

If the harms of methylprednisolone outweigh the benefit, the drug is reduced or stopped, but not abruptly after long use. The label says that if the drug is to be stopped after long-term therapy it should be withdrawn gradually, and that drug-induced adrenal insufficiency can be minimised by gradual dose reduction and may persist for months afterwards. Stopping decisions belong with the prescriber. (Source 16)

Why might someone be low in it or missing it?

Someone can have less methylprednisolone in the blood than expected, or lose its effect, if they are also taking a drug that speeds up its breakdown. The label names phenobarbital, phenytoin and rifampin as enzyme inducers that increase methylprednisolone clearance and may require a higher dose. Separately, people are often simply not on it because the condition does not need a steroid or because the risks outweigh the benefit. (Source 13)

Which whole foods contain it or feed it?

No whole food contains methylprednisolone. One food does change its levels: in a crossover study in ten healthy people, grapefruit juice raised the total exposure to a 16 mg oral dose by 75%. Liquorice (glycyrrhizin) has been shown to slow the clearance of the closely related steroid prednisolone. Neither is a way to obtain the drug; both are reasons the same dose can act more strongly. (Source 27)

What happens if you do not have it?

Not taking methylprednisolone is the normal state for most people. Where it is indicated, going without it means the inflammatory condition runs its own course: in multiple sclerosis relapses, trials show the drug speeds recovery over the first five weeks, with an odds ratio of 0.37 for the relapse worsening or not improving, but the one trial with a year of follow-up found no difference in later disability. In true adrenal insufficiency, replacement steroid is necessary rather than optional. (Source 2)

How can you test for it?

There is no routine blood test to check the methylprednisolone dose. What is tested is its effects: adrenal function after treatment, because a meta-analysis of 74 studies found adrenal insufficiency is common and cannot be excluded by any route, dose or duration, so the authors said the threshold for testing should be low. Blood sugar, blood pressure, potassium, eye pressure and bone density are also monitored during long courses. (Source 18)

References

1. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - ACTIONS. 2026. Read the source
2. The Cochrane database of systematic reviews. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.. 2000. PMID 11034713, DOI 10.1002/14651858.cd001331. Read the source
3. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - INDICATIONS AND USAGE (opening list). 2026. Read the source
4. Lancet (London, England). Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.. 2005. PMID 15936423, DOI 10.1016/s0140-6736(05)66552-x. Read the source
5. The Cochrane database of systematic reviews. Steroids for acute spinal cord injury.. 2012. PMID 22258943, DOI 10.1002/14651858.cd001046.pub2. Read the source
6. Lancet (London, England). Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.. 2015. PMID 26460660, DOI 10.1016/s0140-6736(15)00273-1. Read the source
7. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.. 2021. PMID 32785710, DOI 10.1093/cid/ciaa1177. Read the source
8. DailyMed / Sagent Pharmaceuticals (FDA Structured Product Label). METHYLPREDNISOLONE ACETATE injectable suspension - WARNINGS, Serious Neurologic Adverse Reactions with Epidural Administration. 2025. Read the source
9. JAMA. Oral steroids for acute radiculopathy due to a herniated lumbar disk: a randomized clinical trial.. 2015. PMID 25988461, DOI 10.1001/jama.2015.4468. Read the source
10. European journal of clinical pharmacology. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone.. 2000. PMID 11049012, DOI 10.1007/s002280000171. Read the source
11. Endocrinologia japonica. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone.. 1991. PMID 1752235, DOI 10.1507/endocrj1954.38.167. Read the source
12. Clinical pharmacology and therapeutics. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.. 1986. PMID 3709030, DOI 10.1038/clpt.1986.114. Read the source
13. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - PRECAUTIONS, DRUG INTERACTIONS. 2026. Read the source
14. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - WARNINGS, Ophthalmic Effects through Vaccination. 2026. Read the source
15. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - PRECAUTIONS, General Precautions (cautions in coexisting disease; growth in children). 2026. Read the source
16. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - DOSAGE AND ADMINISTRATION (dose adjustment and gradual withdrawal). 2026. Read the source
17. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - PRECAUTIONS, General Precautions (adrenal insufficiency and dose reduction). 2026. Read the source
18. The Journal of clinical endocrinology and metabolism. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.. 2015. PMID 25844620, DOI 10.1210/jc.2015-1218. Read the source
19. BMJ (Clinical research ed.). Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.. 2017. PMID 28404617, DOI 10.1136/bmj.j1415. Read the source
20. The Journal of clinical endocrinology and metabolism. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.. 2015. PMID 25844620, DOI 10.1210/jc.2015-1218. Read the source
21. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - ADVERSE REACTIONS. 2026. Read the source
22. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - WARNINGS, Immunosuppression and Increased Risk of Infection. 2026. Read the source
23. Lancet (London, England). Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.. 2015. PMID 26135706, DOI 10.1016/s0140-6736(15)61137-0. Read the source
24. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - PRECAUTIONS, General Precautions (multiple sclerosis, dose-dependent complications, tumour lysis). 2026. Read the source
25. Global spine journal. A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of Methylprednisolone Sodium Succinate.. 2017. PMID 29164025, DOI 10.1177/2192568217703085. Read the source
26. DailyMed / PD-Rx Pharmaceuticals Inc (FDA Structured Product Label). METHYLPREDNISOLONE tablet - DOSAGE AND ADMINISTRATION (initial dose range). 2026. Read the source
27. European journal of clinical pharmacology. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone.. 2000. PMID 11049012, DOI 10.1007/s002280000171. Read the source